Cargando…

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) polymerase (PARP) have been approved for ovarian cancer and breast cancer indications. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, He, Liu, Zhao-Yi, Wu, Nayiyuan, Chen, Yong-Chang, Cheng, Quan, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305609/ https://www.ncbi.nlm.nih.gov/pubmed/32563252 http://dx.doi.org/10.1186/s12943-020-01227-0

Ejemplares similares

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
por: Wang, Zhi-Bin, et al.
Publicado: (2023)

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
por: Jackson, Lindsey M, et al.
Publicado: (2022)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
por: Lee, Elizabeth K., et al.
Publicado: (2020)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
por: Rose, Maddison, et al.
Publicado: (2020)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
por: Smith, Hannah L., et al.
Publicado: (2022)

Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
por: Li, He, et al.
Publicado: (2021)

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
por: Mweempwa, Angela, et al.
Publicado: (2019)

Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors
por: Piombino, Claudia, et al.
Publicado: (2022)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
por: Lim, Joline S. J., et al.
Publicado: (2017)

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
por: Kim, Dae-Seok, et al.
Publicado: (2021)

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance
por: Kyo, Satoru, et al.
Publicado: (2022)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
por: Hong, Ting, et al.
Publicado: (2021)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
por: Wu, Yongsong, et al.
Publicado: (2023)

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
por: Francica, Paola, et al.
Publicado: (2018)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
por: Onji, Hiroshi, et al.
Publicado: (2022)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
por: Lau, Chien-Hui, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
por: Prados-Carvajal, Rosario, et al.
Publicado: (2021)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
por: Hu, Hongye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v7lerul6m7eoapmhr4hlqjt0sr